Stay updated on Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Sign up to get notified when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.

Latest updates to the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page
- Check2 days agoChange DetectedA new page revision tag 'v3.5.5' appears, replacing the previous 'v3.5.4'. This marks a small update to the page's revision state and does not change the study content.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedRevision: v3.5.4 now appears on the page, replacing the previous v3.5.3.SummaryDifference0.1%

- Check45 days agoChange DetectedThe page footer has an updated software/UI revision label from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check74 days agoChange DetectedAdded the MeSH term Malignant fibrous histiocytoma to the study's indexing terms.SummaryDifference0.1%

- Check81 days agoChange DetectedRevision: v3.5.0 is now displayed, replacing the previous Revision: v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.